Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals

HIV is known to be present in massive amounts in both resting and actively replicating cells in infected individuals. We tested the combination of didanosine and hydroxyurea, known to suppress viral production in vitro in both of these cell types, in a small number of asymptomatic patients. After 3...

Full description

Saved in:
Bibliographic Details
Published inJournal of acquired immune deficiency syndromes and human retrovirology Vol. 10; no. 1; p. 36
Main Authors Biron, F, Lucht, F, Peyramond, D, Fresard, A, Vallet, T, Nugier, F, Grange, J, Malley, S, Hamedi-Sangsari, F, Vila, J
Format Journal Article
LanguageEnglish
Published United States 01.09.1995
Subjects
Adult
Antiviral Agents - therapeutic use
CD4 Lymphocyte Count
Didanosine - therapeutic use
Drug Therapy, Combination
Drug Tolerance
Female
HIV Seropositivity - drug therapy
Humans
Hydroxyurea - therapeutic use
Male
Middle Aged
Pilot Projects
RNA, Viral - blood
Online AccessGet more information

Cover

More Information
Summary:HIV is known to be present in massive amounts in both resting and actively replicating cells in infected individuals. We tested the combination of didanosine and hydroxyurea, known to suppress viral production in vitro in both of these cell types, in a small number of asymptomatic patients. After 3 months of well tolerated treatment, we observed a large reduction of viral load in the peripheral blood of all 12 patients, down to nonquantifiable levels in 7 of 12 as measured by infectious virus titer, and 6 of 12 as measured by plasma HIV-RNA. In this subgroup of 6 patients, whose baseline HIV-RNA was below 14,000 copies/ml, the median increase in CD4+ count after 90 days of treatment was 244 cells/mm3.
ISSN:1077-9450
DOI:10.1097/00042560-199509000-00005